Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring assay: An exploratory analysis of the IMvigor-010 observation arm.

ctDNA was detected at the MRD timepoint in 66/182 (36%). Of those 66, 58 (88% PPV) had relapsed at analysis. Median DFS from randomization was 3 months if ctDNA-positive versus not reached if negative (HR 5.7, 95% CI 3.8-8.6); median OS 13 months vs not reached (HR 5.7, 95% CI 3.4-9.7).

ASCO Genitourinary Cancers Symposium 2022PubMed 34135506